Paul Stoffels, Galapagos CEO (Andrew Harnik/AP Images)
February 24, 2023 10:02 AM EST
R&D

Gala­pa­gos goes 0-for-3 on in­flam­ma­tion pro­gram as it cuts an ear­ly-stage can­di­date

Lei Lei Wu

News Reporter

Gala­pa­gos has cut an­ti-in­flam­ma­to­ry drug can­di­date GLPG4399 fol­low­ing the com­ple­tion of an ear­ly-stage healthy vol­un­teer tri­al, ac­cord­ing to its 2022 an­nu­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times